Suchergebnisse - "Ando, Kiyohiro"

PubPharm (56)

1

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

enthalten in: Anticancer research | 2024

von Fuchizawa, H. | Ando, K. | Motoi, N. | +10

2

Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma

enthalten in: Biochemical and biophysical research communications | 2023

von Ando, K. | Kurashina, R. | Motoi, N. | +10

3

DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells

enthalten in: International journal of molecular sciences | 2023

von Ando, K. | Suenaga, Y. | Kamijo, T.

4

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors

enthalten in: BMC cancer | 2023

von Parvin, S. | Akter, J. | Takenobu, H. | +9

5

Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma

enthalten in: Cancer diagnosis & prognosis | 2023

von Kurashina, R. | Ando, K. | Inoue, M. | +8

6

The RUNX Family Defines Trk Phenotype and Aggressiveness of Human Neuroblastoma through Regulation of p53 and MYCN

enthalten in: Cells | 2023

von Ando, K. | Nakagawara, A.

7

Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN

enthalten in: Cancer science | 2022

von Shinno, Y. | Takenobu, H. | Sugino, R. | +14

8

Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma

enthalten in: Anticancer research | 2022

von Kurashina, R. | Ando, K. | Inoue, M. | +8

9

FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis

enthalten in: Cancer science | 2022

von Ando, K. | Ohira, M. | Takada, I. | +8

10

Editorial : Neuroblastoma: Signal Crosstalk and Future Insight Into Clinical Trials

enthalten in: Frontiers in oncology | 2022

von Ando, K. | Sanda, T. | Suenaga, Y. | +1

1
2
3
4
5
6
Nächster »
[6]